Please login to the form below

What next for the treatment of Psoriasis in Europe?

Research Director Laurent Chanroux investigates the changing market dynamics in Psoriasis in Europe.

Over the last decade, systemic biologic therapies for Psoriasis (PsO) have become widespread and the development of biological therapies has revolutionized the treatment of the disease. A chronic autoimmune disease, psoriasis has an estimated prevalence of 2.5% in Europe, representing approximately 15 million people, with 20–25% of these suffering from severe disease...

Read the article:

11th April 2017